Identification of genes with abnormal expression changes in acute myeloid leukemia

Genes Chromosomes and Cancer

Volumn 47, Issue 1, 2008, Pages 8-20

  Stirewalt, Derek L ^a   Meshinchi, Soheil ^a,b   Kopecky, Kenneth J ^a   Fan, Wenhong ^a   Pogosova Agadjanyan, Era L ^a   Engel, Julia H ^a   Cronk, Michelle R ^a   Dorcy, Kathleen Shannon ^a   McQuary, Amy R ^c   Hockenbery, David ^a   Wood, Brent ^d   Heimfeld, Shelly ^a   Radich, Jerald P ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b CHILDREN S ONCOLOGY GROUP   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANALYTIC METHOD; ARTICLE; BLAST CELL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; CYCLIN A; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; GENES, NEOPLASM; GENES, WILMS TUMOR; GENETIC MARKERS; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, INTERLEUKIN-3; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

CUCURBITA;

EID: 36549022557     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20500     Document Type: Article

References (101)

1. Affymetrix, Inc. 2003a. Affymetrix I, GeneChip® Expression Analysis Technical Manual. Available at http://www.affymetrix.com/support/technical/ manual/expression_manual.affx. Accessed July 7, 2006.
2. Affymetrix, Inc. 2003b. Affymetrix I, GeneChip® Expression Analysis: Data Analysis Fundamentals. Part Number 701190 Revision 4. Available at http://www.affymetrix.com/support/downloads/manuals/ data_analysis_fundamentals_manual.pdf. Accessed April 23, 2007.
3. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A, Riganelli D, Sebastiani C, Cappelli E, Casciari C, Sciurpi MT, Mariano AR, Minardi SP, Luzi L, Muller H, Di Fiore PP, Frosina G, Pelicci PG. 2003. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 112:1751-1761.
4. Alcalay M, Tiaeci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, Meani N, Diverio D, Bernard F, Tizzoni L, Volorio S, Luzi L, Colombo E, Lo Coco F, Mecucci C, Falini B, Pelicci PG. 2005. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 106:899-902.
5. Anuchapreeda S, Limtrakul P, Thanarattanakorn P, Sittipreechacharn S, Chanarat P. 2006. Inhibitory effect of curcumin on WT1 gene expression in patient leukemic cells. Arch Pharm Res 29:80-87.
6. Aurandt J, Li W, Guan KL. 2006. Semaphorin 4D activates the MAPK pathway downstream of plexin-B1. Biochem J 394:459-464.
7. Aurandt J, Vikis HG, Gutkind JS, Ahn N, Guan KL. 2002. The semaphorin receptor plexin-B1 signals through a direct interaction with the Rho-specific nucleotide exchange factor, LARG. Proc Natl Acad Sci USA 99:12085-12090.
8. Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D. 1997. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90:1217-1225.
9. Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela JM, Terre C, Tigaud I, Castaigne S, Raffoux E, De Botton S, Fenaux P, Dombret H, Prcudhomme C. 2005. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 106:3618-3620.
10. Bolstad BM, Irizarry RA, Astrand M, Speed TP. 2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185-193.
11. Bortoloso E, Pilati N, Megighian A, Tibaldo E, Sandona D, Volpe P. 2006. Transition of Homer isoforms during skeletal muscle regeneration. Am J Physiol Cell Physiol 290:C711-C718.
12. Boyd JM, Gallo GJ, Elangovan B, Houghton AB, Malstrom S, Avery BJ, Ebb RG, Subramanian T, Chittenden T, Lutz RJ, Chinnadurai G. 1995. Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. Oncogene 11:1921-1928.
13. Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M. 2001. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29:365-371.
14. Budel LM, Touw IP, Delwel R, Clark SC, Lowenberg B. 1989. Interleukin-3 and granulocyte-monocyte colony-stimulating factor receptors on human acute myelocytic leukemia cells and relationship to the proliferative response. Blood 74:565-571.
15. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, Dohner H, Pollack JR. 2004. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616.
16. Camos M, Esteve J, Jares P, Colomer D, Rozman M, Villamor N, Costa D, Carrio A, Nomdedeu J, Montserrat E, Campo E. 2006. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 66:6947-6954.
17. Cazzaniga G, Dell'Oro MG, Mecucci C, Giarin E, Masetti R, Rossi V, Locatelli F, Martelli MF, Basso G, Pession A, Biondi A, Falini B. 2005. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood 106:1419-1422.
18. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. 2006. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:351-365.
19. Chiaramonte R, Basile A, Tassi E, Calzavara E, Cecchinato V, Rossi V, Biondi A, Comi P. 2005. A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett 219:113-120.
20. Cilloni D, Gottardi F, De Michcli D, Serra A, Volpe G, Messa F, Rege-Cambrin G, Guerrasio A, Divona M, Lo Coco F, Saglio G. 2002. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16:2115-2121.
21. Clark EA, Golub TR, Lander ES, Hynes RO. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535.
22. Colter M, Jones M, Heimfeld S. 1996. CD34+ progenitor cell selection: Clinical transplantation, tumor cell purging, gene therapy, ex vivo expansion, and cord blood processing. J Hematother 5:179-184.
23. Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, Bullinger L, Frohling S, Dohner H. 2005. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746.
24. Duester G. 2000. Families of retinoid dehydrogenases regulating vitamin A function: Production of visual pigment and retinoie acid. Eur J Biochem 267:4315-4324.
25. Eberhart CG, Wasserman SA. 1995. The pelota locus encodes a protein required for mciotic cell division: An analysis of G2/M arrest in Drosophila spermatogenesis. Development 121:3477-3486.
26. Elissceva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H. 2002. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99:3272-3279.
27. Falini B, Nicoletti I, Martelli MF, Mecucci C. 2007. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): Biological and clinical features. Blood 109:874-875.
28. Gaiger A, Reese V, Disis ML, Cheever MA. 2000. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood 96:1480-1489.
29. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D. 2006. Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 20:2147-2154.
30. Georgantas RW, III, Tanadve V, Malchorn M, Heimfeld S, Chen C, Carr L, Martinez-Murillo F, Riggins G, Kowalski J, Civin CI. 2004. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res 64:4434-4441.
31. Glienke W, Chow KU, Bauer N, Bergmann L. 2006. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds. Leuk Lymphoma 47:1629-1638.
32. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. 1999. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 286:531-537.
33. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A. 1998. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333.
34. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, Kern W, Schoch C. 2005. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106:1189-1198.
35. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink K, Vardiman J, Lister TA, Bloomfield CD. 1999. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. JCO 17:3835-3849.
36. Heuser M, Wingen LU, Steinemann D, Cario G, von Neuhoff N, Tauscher M, Bullinger L, Krauter J, Heil G, Dohner H. Schlegelberger B, Ganser A. 2005. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica 90:1484-1492.
37. Holm C, Ora I, Brunhoff C, Anagnostaki L, Landberg G, Persson JL. 2006. Cyclin A1 expression and associations with disease characteristics in childhood acute lymphoblastic leukemia. Leuk Res 30:254-261.
38. Hsu LC, Chang WC, Yoshida A. 1989. Genomic structure of the human cytosolic aldehyde dehydrogenase gene. Genomics 5:857-865.
39. Huntly BJ, Shigematsu FI, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D, Williams IR, Akashi K, Gilliland DG. 2004. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 6:587-596.
40. Ingenuity Systems. 2006a. FAQs about statistical considerations. Available at https://analysis.ingenuity.com/pa/info/help/ faqs_about_statistical_calculations.htm. Accessed June 12, 2007.
41. Ingenuity Systems. 2006b. Guidelines for publications. Available at https://analysis.ingenuity.com/pa/info/help/guidelines_for_publications.htm. Accessed June 12, 2007.
42. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, Kita K, Hiraoka A, Masaoka T, Nasu K, Kyo K, Dohy H, Nakauchi H, Ishidate T, Akiyama T, Kishimoto T. 1994. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071-3079.
43. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, Miyake S, Tamaki H, Oji Y, Yamagami T, Tatekawa T, Soma T, Kishimoto T, Sugiyama H. 1997. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89:1405-1412.
44. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264.
45. Ishiguro K, Xavier R. 2004. Homer-3 regulates activation of serum response element in T cells via its EVH1 domain. Blood 103:2248-2256.
46. Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR. 2002. A stem cell molecular signature. Science 298:601-604.
47. Keeshan K, He Y, Wouters BJ, Shestova O, Xu L, Sai H, Rodriguez CG, Maillard I, Tobias JW, Valk P, Carroll M, Aster JC, Delwel R, Pear WS. 2006. Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell 10:401-411.
48. Kelly LM, Kutok JL, Williams IR, Boulton CL, Amaral SM, Curley DP, Ley TJ, Gilliland DG. 2002. PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. Proc Natl Acad Svi USA 99:8283-8238.
49. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D. 2005. Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105:1759-1767.
50. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R. 1999. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080.
51. Kobayashi T, Hino S, Oue N, Asahara T, Zollo M, Yasui W, Kikuchi A. 2006. Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. Mol Cell Biol 26:898-911.
52. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. 2001. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759.
53. Kottaridis PD, Gale RE, Langabeer SE, Frew MF, Bowen DT, Linch DC. 2002. Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: Implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100:2393-2398.
54. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR, Armstrong SA. 2006. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442:818-822.
55. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic B, Dahl GV. 2004. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104:2646-2654.
56. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JF. 1994. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648.
57. Lapillonne H, Renneville A, Auvrignon A, Flamant C, Blaise A, Perot C, Lai JL, Ballerini P, Mazingue F, Fasola S, Dehee A, Bellman F, Adam M, Labopin M, Douay L, Leverger G, Preudhomme C, Landman-Parker J. 2006. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24:1507-1515.
58. Lee BH, Williams IR, Anastasiadou E, Boulton CL, Joseph SW, Amaral SM, Curley DP, Duclos N, Huntly BJ, Fabbro D, Griffin JD, Gilliland DG. 2005. FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model. Oncogene 24:7882-7892.
59. Liao C, Wang XY, Wei HQ, Li SQ, Merghoub T, Pandolfi PP, Wolgemuth DJ. 2001. Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. Proc Natl Acad Sci USA 98:6853-6858.
60. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
61. Manion MK, Hockenbery DM. 2003. Targeting BCL-2-related proteins in cancer therapy. Cancer Biol Ther 2:S105-S114.
62. Marcucci G, Baldus CD, Ruppert AS, Radmacher MD, Mrozek K, Whitman SP, Kolitz JE, Edwards CG, Vardiman JW, Powell BL, Baer MR, Moore JO, Perrotti D, Caligiuri MA, Carroll AJ, Larson RA, de la Chapelle A, Bloomfield CD. 2005. Overexpression of the ETS-relatcd gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 23:9234-9242.
63. Marosi C, Koller U, Koller-Weber E, Schwarzinger I, Schneider B, Jager U, Vahls P, Nowotny H, Pirc-Danoewinata H, Steger G, Kreiner G, Wagner B, Lechner K, Lutz D, Bettelheim P, Haas OA. 1992. Prognostic impact of karyotype and immunologic phenotype in 125 adult patients with de novo AML. Cancer Genet Cytogenet 61:14-25.
64. Miwa H, Beran M, Saunders GF. 1992. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6:405-409.
65. Miyagi T, Ahuja H, Kubota T, Kubonishi I, Koeffler HP, Miyoshi I. 1993. Expression of the candidate Wilm's tumor gene, WT1, in human leukemia cells. Leukemia 7:970-977.
66. Mizuki M, Sehwable J, Steur C, Choudhary C, Agrawal S, Sargin B, Steffen B, Matsumura I, Kanakura Y, Bohmer FD, Muller-Tidow C, Berdel WE, Serve H. 2003. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 101:3164-3173.
67. Munoz L, Nomdedeu JF, Lopez O, Carnicer MJ, Bellido M, Aventin A, Brunet S, Sierra J. 2001. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 86:1261-1269.
68. Nakamaki T, Hamano Y, Hisatake J, Yokoyama A, Kawakami K, Tomoyasu S, Honma Y, Koeffler P. 2003. Elevated levels of cyclin A1 and A (A2) mRNA in acute myeloid leukaemia are associated with increased survival. Br J Haematol 123:72-80.
69. National Cancer Institute (NCI). 2004. SEER Cancer Statistics Review 1975-2001.
70. National Center for Biotechnology Information (NCBI). GEO: Gene expression omnibus. Available at http://www.ncbi.nlm.nih.gov/geo/. Accessed June 23, 2006.
71. Neben K, Schnittger S, Brors B, Tews B, Kokocinski F, Haferlach T, Muller J, Hahn M, Hiddemann W, Lichter P, Schoch C. 2005. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 24:1580-1588.
72. Nishida S, Hosen N, Shirakata T, Kanato K, Yanagihara M, Nakatsuka S, Hoshida Y, Nakazawa T, Harada Y, Tatsumi N, Tsuboi A, Kawakami M, Oka Y, Oji Y, Aozasa K, Kawase I, Sugiyama H. 2006. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107:3303-3312.
73. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D. 2005. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 23:752-760.
74. Perrot V, Vazquez-Prado J, Gutkind JS. 2002. Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated Rho GEF (LARG) and PDZ-RhoGEF. J Biol Chem 277:43115-43120.
75. Ritter M, Kattmann D, Teichler S, Hartmann O, Samuelsson MK, Burchert A, Bach JP, Kim TD, Berwanger B, Thiede C, Jager R, Ehninger G, Schafer H, Ueki N, Hayman MJ, Eilers M, Neubauer A. 2006. Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia. Leukemia 20:437-443.
76. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu HC, Mahfouz R, Raimondi SC, Lenny N, Patel A, Downing JR. 2003. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102:2951-2959.
77. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U. 2002. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 100:2132-2137.
78. Schmid D, Heinze G, Linnerth B, Tisljar K, Kusec R, Geissler K, Sillaber C, Laczika K, Mitterbauer M, Zochbauer S, Mannhalter C, Haas OA, Lechner K, Jager U, Gaiger A. 1997. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 11:639-643.
79. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Saucrland CM, Serve H, Buchner T, Haferlach T, Hiddemann W. 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59-66.
80. Schwarzinger I, Valent P, Koller U, Marosi C, Schneider B, Haas O, Knapp W, Lechner K, Bettelheim P. 1990. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol 8:423-430.
81. Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, Pastan I, Wittig S, Pfaffendorf N, Voigt A, Zintl F, Gruhn B. 2006. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 12:2434-2341.
82. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, Radich JP. 2001. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589-3595.
83. Stirewalt DL, Pogosova-Agadjanvan EL, Khalid N, Hare DR, Ladne PA, Sala-Torra O, Zhao LP, Radich JP. 2004. Single-stranded linear amplification protocol results in reproducible and reliable microarray data from nanogram amounts of starting RNA. Genomics 83:321-331.
84. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 100:9440-9445.
85. Storms RW, Trujillo AP, Springer JB, Shah L, Colvin OM, Ludeman SM, Smith C. 1999. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci USA 96:9118-9123.
86. Taniguchi A, Suga R, Matsumoto K. 2000. Expression and transcriptional regulation of the human alpha1, 3-fucosyltransferase 4 (FUT4) gene in myeloid and colon adenocarcinoma cell lines. Biochem Biophys Res Commun 273:370-376.
87. Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, Latagliata R, Mariani G, Rossini A, Battistini A, Lo-Coco F, Peschle C. 2002. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood 100:2980-2988.
88. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. 2002. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335.
89. Tohda S, Nara N. 2001. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma 42:467-472.
90. Toren A, Bielorai B, Jacob-Hirsch J, Fisher T, Kreiser D, Moran O, Zeligson S, Givol D, Yitzhaky A, Itskovitz-Eldor J, Kventsel I, Rosenthal E, Amariglio N, Rechavi G. 2005. CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. Stem Cells 23:1142-1153.
91. Tse W, Meshinchi S, Alonzo TA, Stirewalt DL, Gerbing RB, Woods WG, Appelbaum FR, Radich JP. 2004. Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. Blood 104:3058-3063.
92. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Lowenberg B, Delwel R. 2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628.
93. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, Uitterlinden AG, Erpelinck CA, Deiwel R, Lowenberg B, Valk PJ. 2005. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106:3747-3754.
94. Walzer T, Galibert L, Comeau MR, De Smedt T. 2005. Plexin C1 engagement on mouse dendritic cells by viral semaphorin A39R induces actin cytoskeleton rearrangement and inhibits integrin-mediated adhesion and chemokine-induced migration. J Immunol 174:51-59.
95. Watkins WM, Clarke JL. 2001. The genetic regulation of fucosylated and sialylated antigens on developing myeloid cells. Adv Exp Med Biol 491:231-265.
96. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, Harvey R, Ar K, Xu Y, Kopecky KJ, Ankerst DP, Gundacker H, Slovak ML, Mosquera-Caro M, Chen IM, Stirewalt DL, Murphy M, Schultz FA, Kang H, Wang X, Radich JP, Appelbaum FR, Atlas SR, Godwin J, Willman CL. 2006. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108:685-696.
97. Xu XL, Olson JM, Zhao LP. 2002. A regression-based method to identify differentially expressed genes in microarray time course studies and its application in an inducible Huntington's disease transgenic model. Hum Mol Genet 11:1977-1985.
98. Yu J, Leisenring W, Fritschle W, Heimfeld S, Shulman H, Bensinger Wl, Holmberg LA, Rowley SD. 2000. Enumeration of HPC in mobilized peripheral blood with the Sysmex SE9500 predicts final CD34+ cell yield in the apheresis collection. Bone Marrow Transplant 25:1157-1164.
99. Zhao LP, Prentice R, Breeden L. 2001. Statistical modeling of large microarray data sets to identify stimulus-response profiles. Proc Natl Acad Sci USA 98:5631-5636.
100. Zollo M, Andre A, Cossu A, Sini MC, D'Angelo A, Marino N, Budroni M, Tanda F, Arrigoni G, Palmieri G. 2005. Overexpression of h-prune in breast cancer is correlated with advanced disease status. Clin Cancer Res 11:199-205.
101. Zweidler-McKay PA, He Y, Xu L, Rodriguez CG, Karnell FG, Carpenter AC, Aster JC, Allman D, Pear WS. 2005. Notch signaling is a potent inducer of growth arrest and apoptosis in a wide range of B-cell malignancies. Blood 106:3898-3906.